The abstract was selected as one of the best abstracts for poster presentation and is therefore also chosen to be presented orally in one of the moderated poster sessions.
'We are very pleased that our presentation of the PK study results was selected as one of the best abstracts for poster presentation at UEGW, one of the largest gastroenterology congresses in the world,' said
The PK study results will be presented by principal investigator
Results from the PK study included PK data from 7 patients with moderate to severe ulcerative colitis treated with doses of 500 mg of cobitolimod administered rectally. The systemic uptake of cobitolimod was limited both for patients with active disease and in clinical remission, with the majority of patients having undetectable levels of cobitolimod in the plasma after 8 hours. Even though it was a small-scale open-label study, it was encouraging that 4 out of 7 patients achieved clinical remission at week 6 after receiving two doses of 500 mg cobitolimod. In line with previous studies, cobitolimod was well tolerated and no serious adverse events were reported in the study.
During UEGW, taking place in
Contact:
Tel: +46 8 122 038 50
Email: jenny.sundqvist@indexpharma.com
InDex is a pharmaceutical development company focusing on immunological diseases where there is a high unmet medical need for new treatment options. The company's lead asset is the drug candidate cobitolimod, which is being evaluated in the phase III program CONCLUDE as a novel treatment of moderate to severe ulcerative colitis - a debilitating, chronic inflammation of the large intestine. InDex has also developed a platform of patent protected discovery stage substances, so called DNA based ImmunoModulatory Sequences (DIMS), with the potential to be used in the treatment of various immunological diseases.
InDex is based in
(C) 2023 Electronic News Publishing, source